Brief: Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI
06/02/2026 13:30
Feb 6 (Reuters) - Clearmind Medicine Inc CMND.O: CLEARMIND MEDICINE ENTERS INTO DEVELOPMENT AGREEMENT TO ADVANCE INTRANASAL FORMULATION FOR ITS PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN MEAI Source text: ID:nGNX8L1NC0 Further company coverage: CMND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polyrizon
See all newsBrief: Polyrizon Files For U.S. Patent Application To Expand Ip Moat Around Intranasal Drug-Delivery Platform
Brief: Polyrizon Advances Towards Human Clinical Trials Secures First U.S. Clinical Site For Nasarix™ Allergy Blocker Clinical Trial
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:58 AM
Enters Agreements For Registered Direct Offering Of Ordinary Shares And Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America